Clinical Vignette in Antiretroviral Therapy: Rash Illness

Symonds W , Cutrell A , Edwards M , et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002; 24(4): 565-573.

Hetherington S , Hughes A , Mosteller , et al. HLA-B57 and TNF-alpha variants associated with hypersensitivity reactions to abacavir among HIV-1-positive subjects. 9th Conference on Retroviruses and Opportunistic Infections. February 24-28, 2002. Seattle, WA. (Abstract 92).

Hetherington S , Steel H , Naderer O , et al. Hypersensitivity reactions during therapy with abacavir: analysis of 636 cases for clinical presentation and risk factors. 7th Conference on Retroviruses and Opportunistic Infections. January 30-February 2, 2000. San Francisco, CA. (Abstract 60).

Stern J , Love J , Robinson P , Lanes S , Imperiale M , Mayers D . Hepatic safety of nevirapine: results of the Boehringer Ingelheim Viramunereg. Hepatic Safety Project. 14th International AIDS Conference. July 7-12, 2002. Barcelona, Spain. (Abstract LbOr15).

Pollard RB , Robinson P , Dransfield K . Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20(6):1071-1092.

Berger TG , Obuch ML , Goldschmidt RH . Dermatologic manifestations of HIV infection. Am Fam Physician 1990; 41(6):1729-1742.

Lipman M , Gluck T , Johnson M , editors. Atlas of Differential Diagnosis in HIV Disease. New York: Parthenon Publishing Group; 1995. Pages 35-50.

Kaplan AP . Clinical Practice. Chronic urticaria and angioedema. N Eng J Med 2002; 346(3):175-179.

The diagnosis and management of urticaria: a practice parameter part I: acute urticaria/angioedema part II: chronic urticaria/angioedema. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2000; 85(6 Pt 2):521-544.